Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Latest Financial Results
Q3 2024
Quarter Ended Sep 30, 2024
Latest 10-K
Financials
View the latest financials